API | pipamperone

pipamperone Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Pipamperone, sold under the brand name Dipiperon, is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia and as a sleep aid for depression. It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan. Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963. ^Wikipedia

Chemistry

SMILES: NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1
InChIKey: AXKPFOAXAHJUAG-UHFFFAOYSA-N
Mol. Mass: 375.49
ALogP: 2.59 Partition coefficient
ChEMBL Molecule:
pipamperone

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (1)

Schizophrenia

Experimental Indications - Clinical Trial Phases 1-4 (7)

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Depressive Disorder, Major (Phase 3)

Psychophysiologic Disorders (Phase 3)

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue